ICCC CEO Paul Te Boekhorst Acquires Additional Shares
ICCC's CEO Paul Te Boekhorst purchased 8,000 shares, boosting his stake in the company.
Key Points
- On June 18, 2026, ICCC's CEO Paul Te Boekhorst bought 8,000 shares at $9.50 each, totaling $76,000.
- Shares of ICCC traded near $9.49 on Monday, with significant institutional activity from major funds.
- Vanguard Capital opened a new ICCC position, while Morgan Stanley increased its stake by 77.8%.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
ICCC's President and CEO, Paul Te Boekhorst, has increased his investment in the company by buying 8,000 shares. The purchase, made on June 18, 2026, was at an average price of $9.50 per share, totaling $76,000. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at ImmuCell Corporation
Paul Te Boekhorst, ICCC's President and CEO, bought 8,000 shares on June 18, 2026, at $9.50 per share, marking a personal investment of $76,000. This purchase was not made under a Rule 10b5-1 trading plan. Other recent insider transactions include David Scott Tomsche, Paul Wainman, Kathy Turner, and Gloria Basse, each acquiring shares on April 15, 2026.
Other Institutional Activity in ICCC
Institutional investors have been active in ICCC. Vanguard Capital Management LLC opened a new position with 260,327 shares valued at approximately $1,647,870. Morgan Stanley increased its holdings by 97,000 shares, a 77.8% increase, bringing its total to 221,716 shares worth about $1,403,462. Renaissance Technologies LLC added 1,100 shares, a 0.7% increase, to reach 151,789 shares valued at $960,824. Meanwhile, Cresset Asset Management, LLC and Bleichroeder LP maintained their positions without change, and Geode Capital Management, LLC reduced its stake by 6,492 shares, a 9.0% decrease, ending with 65,765 shares.
ImmuCell Corporation Stock Down 4.5%
Shares of ICCC traded near $9.49 on Monday. The stock has seen significant activity from both insiders and institutional investors, indicating ongoing interest and investment. Institutional movements and insider transactions often provide insights into a company's potential future performance.
$ICCC stock price
Daily closing prices, year to date. Not investment advice.
Bottom Line
Paul Te Boekhorst's recent purchase of ICCC shares underscores his confidence in the company's future. Insider buying is often watched closely by investors as a potential signal of a company's prospects. Institutional activity also highlights interest in ICCC, with major funds like Vanguard Capital and Morgan Stanley adjusting their positions. As always, remember that these insider and institutional reports reflect past actions and may not indicate current positions.
Get ImmuCell Corporation alerts
New 13F filings, insider trades, and analyst moves on $ICCC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.